Friday, May 10, 2019

Immunogen Posts Earnings Report Chalk full of Beta

If you don't love the reporting requirements of public companies, that you aren't living.  Want to know how much the CEO makes - its in there.  Want to know their 3 mo, 6 mo, and 2 year outlook?  Its in there.  Want to know whats happening with Mirvetuximab?  Me too...

ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results

There is a ton inside of this report worth checking out.  A few highlights are:
  • Top-line results announced from the Phase 3 FORWARD I study of mirvetuximab soravtansine ... suggest a favorable benefit-risk profile in this population. (i.r. mirvetuximab isn't dead as a monotherapy, even in the short term)
  • Meet with the U.S. Food and Drug Administration (FDA) in Q2 to discuss a potential path to registration for mirvetuximab soravtansine as a monotherapy for the treatment of platinum-resistant ovarian cancer patients with high FRα expression.
And because you asked:

I still can't believe they make this stuff public.  Immunogen CEO Mark Enyedy made $2.7 mill in 2017.  Do you work at a public company?  Google it.  Maybe your boss is on there.  Mine was when I worked at a small startup in Mountain View. 

(PS. In case you were wondering.  I am using Beta as a rock-climbing term used to reference route information, not as the financial form of Beta where it references stock price correlation to SP500 movements.  Which to be fair is my second favorite kind of beta)

No comments:

Post a Comment